BACKGROUND:Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non-Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. METHODS: Data on patients with recurring NHL treated with yttrium Y 90 ibritumomab tiuxetan in 4 clinical trials were reviewed to identify patients with a long-term response, defined as a time to progression of 12 months or longer. RESULTS: Long-term responses were seen in 37% (78/211) of patients. At a median follow-up of 53.5 months (range, 12.7-88.9) the median duration of response was 28.1 months and the median time to progression was 29.3 months. A third of these patients had been treated with at least 3 previous therapies, and 37% of them had not responded to their last therapy. The findings in patients with follicular lymphoma (n=59) were similar to those in the overall population of long-term responders. The estimated overall survival at 5 years was 53% for all patients treated with 90Y ibritumomab tiuxetan and 81% for long-term responders. CONCLUSIONS: A single dose of 90Y ibritumomab tiuxetan can produce durable responses and prolonged overall survival in a substantial number of patients in whom previous therapies have failed. Copyright (c) 2007 American Cancer Society
RCT Entities:
BACKGROUND: Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non-Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. METHODS: Data on patients with recurring NHL treated with yttrium Y 90 ibritumomab tiuxetan in 4 clinical trials were reviewed to identify patients with a long-term response, defined as a time to progression of 12 months or longer. RESULTS: Long-term responses were seen in 37% (78/211) of patients. At a median follow-up of 53.5 months (range, 12.7-88.9) the median duration of response was 28.1 months and the median time to progression was 29.3 months. A third of these patients had been treated with at least 3 previous therapies, and 37% of them had not responded to their last therapy. The findings in patients with follicular lymphoma (n=59) were similar to those in the overall population of long-term responders. The estimated overall survival at 5 years was 53% for all patients treated with 90Y ibritumomab tiuxetan and 81% for long-term responders. CONCLUSIONS: A single dose of 90Y ibritumomab tiuxetan can produce durable responses and prolonged overall survival in a substantial number of patients in whom previous therapies have failed. Copyright (c) 2007 American Cancer Society
Authors: S Ferrero; A Pastore; C W Scholz; R Forstpointner; A Pezzutto; L Bergmann; L Trümper; J Finke; U Keller; P Ghione; R Passera; W Hiddemann; O Weigert; M Unterhalt; M Dreyling Journal: Leukemia Date: 2015-08-05 Impact factor: 11.528
Authors: Sébastien Baechler; Robert F Hobbs; Heather A Jacene; François O Bochud; Richard L Wahl; George Sgouros Journal: J Nucl Med Date: 2010-12 Impact factor: 10.057
Authors: Robert M Sharkey; Habibe Karacay; Samuel Litwin; Edmund A Rossi; William J McBride; Chien-Hsing Chang; David M Goldenberg Journal: Cancer Res Date: 2008-07-01 Impact factor: 12.701
Authors: Thomas E Witzig; Gregory A Wiseman; Matthew J Maurer; Thomas M Habermann; Ivana N M Micallef; Grzegorz S Nowakowski; Stephen M Ansell; Joseph P Colgan; David J Inwards; Luis F Porrata; Brian K Link; Clive S Zent; Patrick B Johnston; Tait D Shanafelt; Cristine Allmer; Yan W Asmann; Mamta Gupta; Zuhair K Ballas; Brian J Smith; George J Weiner Journal: Am J Hematol Date: 2013-06-12 Impact factor: 10.047